Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840245 | 0.99 | NCF1 (0.55) | NCF1SMN1; SMN2POLBCHKAALDH1A1 | |
| SCHEMBL4846896 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2POLBCHKAALDH1A1TDP1 | |
| SCHEMBL4850572 | 0.82 | PRMT6 (0.56) | SMN1; SMN2POLBCHKAALDH1A1TDP1 | |
| SCHEMBL4840229 | 0.82 | DPP8 (0.41) | NCF1SMN1; SMN2CHKAALDH1A1TDP1 | |
| SCHEMBL4844432 | 0.81 | PRMT6 (0.58) | NCF1SMN1; SMN2POLBCHKAALDH1A1 | |
| SCHEMBL4846900 | 0.77 | CYP2D6 (0.48) | SMN1; SMN2ALDH1A1TDP1CYP2D6CYP2C19 | |
| SCHEMBL4840236 | 0.75 | CYP2D6 (0.46) | SMN1; SMN2CHKAALDH1A1TDP1CYP2D6 | |
| SCHEMBL1936431 | 0.75 | NCF1 (0.69) | NCF1SMN1; SMN2ALDH1A1TDP1CYP2D6 | |
| SCHEMBL22957889 | 0.75 | ALDH1A1 (0.58) | NCF1SMN1; SMN2POLBALDH1A1HRH3 | |
| SCHEMBL4839412 | 0.75 | KMT2A (0.51) | NCF1CHKADPP8PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368462-B1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-06 | — | — | US | claimed |
| US-7368462-B1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080058423-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058423-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC4R | NCF1 1524/4885SMN1; SMN2 4681/4885POLB 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.